As has been the case with many small-cap biotech stocks amid the coronavirus pandemic, traders have gotten excited in recent weeks about the stock examined in today’s article, one which, not that long ago, had fallen to as low as 10 cents per share and appeared to be heading towards bankruptcy. However, the stock in question generated similar excitement during past disease outbreaks, only for that enthusiasm to fade and shares to crash. Could this time be different – or is history likely to repeat? CLICK HERE.